Immatics N.V.

Immatics Biotechnologies GmbH

General information
Immatics N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany

Contact person: Andrea Mayer-Mokler, Vice President Global Head of Clinical Sciences
Company main phone: +49 (7071) 53970
Company main fax:  +49 (7071) 5397900
Website:  https://www.immatics.com
Year founded:2000
Source of foundation:Spin-off from university
Name of foundation source:H.G. Rammensee's laboratory at the University of Tübingen, Germany
No. of employees: Worldwide:  646
Corporate description / mission:
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. The company's clinical ACTengine® programs are based on genetically engineering a patient’s own, autologous T cells with novel TCRs designed to recognize the cancer target on the tumor. The engineered T cells (TCR-T) aim to induce a robust and specific anti-tumor attack to fight the cancer. The company's TCER® IMA401 is Immatics’ most advanced TCER® molecule from the Bispecifics pipeline that targets an HLA-A*02-presented (human leukocyte antigen) peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 (“MAGEA4/8”). The MAGEA4/8 peptide has been identified and validated by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT® and is presented at a 5-fold higher copy number per tumor cell than the MAGEA4 peptide targeted in other clinical trials.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2020
Remarks on ownership / listings
In July 2020, Immatics started trading on NASDAQ as a result of a business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA; or “Arya”), a special purpose acquisition, sponsored by Perceptive Advisors.

In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston Texas.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Antibodies
  • Cell therapy
  • Immunotherapy
  • Peptides
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • In-licensing
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:7
Phase I:2
Phase II:2
Description of products:
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.
Special IP situation:
The XPRESIDENT technology is protected by granted patents and patent applications.
Technology used:
XPRESIDENT™
XCEPTOR®
Financing details
Fiscal year (end of) 2024
Revenues:USD 163.14M
R&D expenses:USD 155.02M
Net earnings:USD 15.93M
Cash:USD 247.85M
Total liabilities:USD 126.99M
No. of shares:121'550'000
Market cap. / valuation:USD 743.89M
Collaborations & Clients
Partnering strategy / collaborations:
Editas
BMS
Moderna, etc.
X